DPC-423 Bristol-Myers Squibb

Current Opinion in Investigational Drugs

Volumn 3, Issue 2, 2002, Pages 252-254

  Taglialatela, Maurizio ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 [3 (AMINOMETHYL)PHENYL] N [3 FLUORO 2' (METHYLSULFONYL)[1,1' BIPHENYL] 4 YL] 3 (TRIFLUOROMETHYL) 1H PYRAZOLE 5 CARBOXAMIDE; BLOOD CLOTTING FACTOR 10A INHIBITOR; DALTEPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT TICK ANTICOAGULANT PEPTIDE; SULFONAMIDE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG METABOLISM; DRUG SYNTHESIS; EXPERIMENTAL MODEL; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; THROMBOSIS;

ANIMALS; ANTITHROMBIN III; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; DISEASE MODELS, ANIMAL; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; FACTOR XA; HUMANS; PYRAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONES; THROMBOSIS;

EID: 0036225285     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Isoxazolines and isoxazoles as factor Xa inhibitors
2. The design and synthesis of orally bioavailable noncovalent factor Xa inhibitors
3. 27th National Medicinal Chemistry Symposium (Part IV), Kansas, MO, USA
4. American Chemical Society 220th National Meeting (Part XV) Medicinal Chemistry Division - Cardiovascular Symposium, Washington DC, USA
5. Antithrombotic effects of DPC 423, a potent and orally active nonepeptide factor Xa inhibitor, in a rabbit model of thrombosis
6. American Heart Association 73rd Scientific Sessions - Overnight Report (Part II) New Orleans, LA, USA
7. Discovery of 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2′-(methylsulfonyl)-[1,1′-biph enyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation Factor Xa
8. Discovery of DPC602: Development of (4-methoxyphenyl)- and (2-(aminomethyl)phenyl) pyrazole inhibitors of factor Xa
9. Discovery of DPC602: Ortho-substituted phenylpyrazoles as potent, orally bioavailable inhibitors of factor X
10. New advances in the discovery of thrombin and factor Xa inhibitors
11. Preparation of pyrrolidine and isoxazolidine benzamidines as potent inhibitors of coagulation factor Xa
12. In vitro characteristics of DPC 423, a novel anticoagulant specific for coagulation factor Xa
13. Pharmacokinetics and antithrombotic efficacy of the selective factor Xa inhibitor DPC 423 in dogs
14. Bristol-Myers Squibb acquires DuPont Pharmaceuticals Company